Loading…
Loading…
Elixinol Wellness Limited (ELLXF) Shareholder/Analyst Call Prepared Remarks Transcript
Elixinol Wellness Limited (ELLXF) Discusses New National Distribution Agreement and Capital Structure Reset Transcript
Elixinol Wellness Limited (ELLXF) Q4 2025 Earnings Call Transcript
Elixinol Wellness Limited (OTCMKTS:ELLXF - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 46 shares, a decrease of 43.2% from the November 30th total of 81 shares. Based on an average daily volume of 2,792 shares,
SYDNEY , Feb. 2, 2024 /PRNewswire/ -- Elixinol Wellness Limited (ASX: EXL) continues to be a pioneer in the global hemp industry, with the release of a new paper into the safety of Elixinol Hemp Extract in leading scientific publication, Journal of Toxicology. The paper, entitled "Safety of Elixinol Hemp Extract: In VitroGenetic Toxicity and Subchronic Toxicity in Rat", reports on safety studies of Elixinol Hemp Extract in rats and concludes that the Extract is safe to use and does not have any adverse effects at the highest dose tested.
Elixinol Wellness Ltd (ASX:EXL, OTCQB:ELLXF) has entered into a three-year exclusive licensing agreement with CBD Health Foods Ltd, trading as British Cannabis, to manufacture, market and sell CBD products across the UK. The agreement follows the company's recent decision to cease trading in the UK and EU markets, and move to an indirect route to market by seeking a licensing partner in the UK.
Elixinol Wellness Ltd has more than 18 months of funding in hand to take advantage of an improving outlook in the US and Australia. With a steadily reducing cost base and with more optimisation initiatives on foot, the leading player in the hemp-derived food and CBD industry, is well-funded with A$16.1 million in cash and an additional A$1.9 million expected from US Employee Retention Credits.
Elixinol Wellness Ltd (ASX:EXL, OTCQB:ELLXF, FRA:E8M) has tabled its interim financial results for the 2021 financial year, recording a 53% improvement in adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) on the previous corresponding period (PCP). The hemp-focused ASX-lister recorded a narrower $7.1 loss over FY21's first half from the $15.2 million tabled at the same time last year, and marking the best EBIDTA result since the first half of 2019.
No recent filings indexed.